227 prescriptions for the drug Addyi, designed to enhance libido in women during menopause, were issued from 17 October to 6 November in the United States, Bloomberg reported, citing data from Bloomberg Intelligence. The agency notes that in 1998, the first month of Viagra sales means was marked by 598,452 prescription (IMS Health’s data).
Addyi stimulates biochemical processes in brain that are associated with disorders of sexual desire in premenopausal period. The drug is manufactured by Sprout, a member of the International Pharmaceutical Holding Valeant.
Bloomberg noted that clinical trials showed Addyi acts only 10% more effective than placebo and, at the same time, increases risk of serious side effects such as hypotension and dizziness. To minimize these effects, women are advised to abstain from alcohol during the course of treatment.
On of probable reasons for the low sales level may be frustration of potential buyers learned that Addyi does not act the same way as means to increase potency in men. Another reason may be the high price. Although one Addyi pill costs $ 26, which is about the same as Viagra, the drug must be taken every day for women, and the monthly cost is $ 780.
Office of FDA Food and Drug Administration has approved the drug’s release in August after two previous rejections. Doctors can prescribe Addyi only after receiving the certificate, which is issued after reviewing a 10-minute online course on rules of the drug’s application.
Head of Valeant Michael Pearson told Bloomberg that so far, only about 5,600 doctors have been permitted to prescribe Addyi. This is about 1% of the number of gynecologists and general practitioners in the US.
Last year, total sales of male potency stimulant Viagra and Cialis was $ 3.98 billion, says Bloomberg.
source: bloomberg.com
Addyi stimulates biochemical processes in brain that are associated with disorders of sexual desire in premenopausal period. The drug is manufactured by Sprout, a member of the International Pharmaceutical Holding Valeant.
Bloomberg noted that clinical trials showed Addyi acts only 10% more effective than placebo and, at the same time, increases risk of serious side effects such as hypotension and dizziness. To minimize these effects, women are advised to abstain from alcohol during the course of treatment.
On of probable reasons for the low sales level may be frustration of potential buyers learned that Addyi does not act the same way as means to increase potency in men. Another reason may be the high price. Although one Addyi pill costs $ 26, which is about the same as Viagra, the drug must be taken every day for women, and the monthly cost is $ 780.
Office of FDA Food and Drug Administration has approved the drug’s release in August after two previous rejections. Doctors can prescribe Addyi only after receiving the certificate, which is issued after reviewing a 10-minute online course on rules of the drug’s application.
Head of Valeant Michael Pearson told Bloomberg that so far, only about 5,600 doctors have been permitted to prescribe Addyi. This is about 1% of the number of gynecologists and general practitioners in the US.
Last year, total sales of male potency stimulant Viagra and Cialis was $ 3.98 billion, says Bloomberg.
source: bloomberg.com